The proto-oncogene c-Myc plays critical roles in human malignancies including chronic myeloid leukemia (CML), suggesting that the discovery of specific agents targeting c-Myc would be extremely valuable for CML treatment. The gene discussed is MYC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.